孟鲁司特辅助治疗小儿肺炎支原体肺炎的有效性探究

摘要

Objective:To explore curative effect and safety of the auxiliary treatment of Montelukast on pediatric mycoplasma pneumonia.Method:78 cases of children with mycoplasma pneumonia were selected,which were admitted in our hospital from March 2012 to September 2013,they were randomly divided into two groups.In the control group,37 cases were given sequential therapy of “static drop-oral” azithromycin and conventional oral,41 cases in the control group were given Montelukast on the basis of the control group,and then comprehensive compared for the therapeutic outcome of the two groups after 14 days treatment.Result:The total effective rate of experimental group(90.24%) was significantly higher than the control group(72.97%),and the difference between two groups was statistically significant(P<0.05),the experimental group was less than the control group on the fade time of clinical signs,such as cough,fever, lung signs(P<0.05).There was no adverse reaction related to Montelukast.Conclusion:The effect of the auxiliary treatment of Montelukast on pediatric mycoplasma pneumonia is remarkable,and high safety,worthy of clinical popularization and application.%目的：分析孟鲁司特用于临床辅助治疗小儿肺炎支原体肺炎的疗效及安全性。方法：将2012年3月-2013年9月笔者所在医院收治的78例肺炎支原体肺炎患儿随机分为两组，对照组37例，给予“静滴-口服”阿奇霉素序贯治疗及常规对症口服；试验组41例，在对照组的基础上再加服孟鲁司特，治疗14 d后对两组患儿治疗结果进行综合比较。结果：试验组治疗总有效率(90.24%)明显高于对照组(72.97%)，组间比较差异有统计学意义(P<0.05)；试验组患儿咳嗽、发热、肺部体征等临床症状体征消退所需时间明显少于对照组(P<0.05)。试验组未见孟鲁斯特相关的可疑不良反应。结论：孟鲁司特用于临床辅助治疗小儿肺炎支原体肺炎效果显著，安全性高，值得临床推广应用。